NCT06173986View on ClinicalTrials.gov

Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 10, 2023

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2027

Conditions
Esophageal Squamous Cell CarcinomaUnresectable Locally Advanced Esophageal Cancer
Interventions
DRUG

PD-1inhibitor

PD-1 inhibitor, Q3W, until disease progression or unacceptable toxicity or treatment reaches 1 year

DRUG

nab-paclitaxel + cisplatin

Induction phase: nab-paclitaxel + cisplatin, Q3W × 2 cycles; Concurrent ICRT phase: nab-paclitaxel + cisplatin, QW × 5 cycles

RADIATION

Radiotherapy

Primary tumor and metastatic lymph nodes, DT:45-50Gy/25fx, starting within 4 weeks following the completion of the last induction immunochemotherapy cycle

Trial Locations (1)

Unknown

RECRUITING

Shanghai Chest Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Chest Hospital

OTHER